Related Experiment Video
Updated: May 24, 2026
07:24
Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing
Published on: February 10, 2023
Alternative reliable method for cytochrome P450 2D6 poor metabolizers genotyping
E Pindurová1, A Zourková, J Zrůstová
1Department of Applied Neuroscience, Faculty of Medicine, Central European Institute of Technology (CEITEC), Brno, Czech Republic. noprecejaef@seznam.cz
Molecular Biotechnology
|February 28, 2012
Summary
High-resolution melting analysis (HRM) is a fast, reliable method for genotyping cytochrome P-450 (CYP) 2D6 nonfunctional alleles. This closed-tube assay accurately identifies common CYP2D6 gene variants in Caucasian patients, aiding drug metabolism studies.
Area of Science:
- Pharmacogenomics
- Molecular Diagnostics
- Genetics
Background:
- Cytochrome P-450 (CYP) 2D6 genetic variations significantly impact drug metabolism, particularly for commonly prescribed medications.
- Identifying nonfunctional CYP2D6 alleles is crucial for personalized medicine and optimizing drug therapy.
- Current genotyping methods can be time-consuming and costly.
Purpose of the Study:
- To adapt and validate high-resolution melting curve analysis (HRM) for rapid and cost-effective genotyping of common CYP2D6 nonfunctional alleles.
- To assess the accuracy of HRM in distinguishing wild-type, heterozygous, and homozygous genotypes for specific CYP2D6 single-nucleotide polymorphisms (SNPs) in a Caucasian population.
Main Methods:
- High-resolution melting curve analysis (HRM) was applied to polymerase chain reaction (PCR) amplicons of common CYP2D6 SNPs (1846G>A, 2988G>A, 100C>T, 2549delA, 2615_2617delAAG, 1707delT).
- Short amplicons (≤148 bp) were analyzed in 91 Caucasian patients undergoing paroxetine therapy.
- Melting curve shapes after fluorescence normalization were used to differentiate genotypes.
Main Results:
- HRM accurately distinguished wild-type, homozygous, and heterozygous samples based on unique melting curve profiles.
- High concordance rates were observed: 92.6% for 1846G>A heterozygotes, 96% for 100C>T heterozygotes, and 100% for 2988G>A, 2549delA, 2615_2617delAAG, and 1707delT heterozygotes.
- All homozygous genotypes were identified with 100% accuracy.
Conclusions:
- HRM is a simple, rapid, specific, and sensitive closed-tube method for reliable CYP2D6 genotyping.
- This technique eliminates the need for real-time PCR, labeled probes, or post-PCR processing, making it suitable for routine diagnostics.
- HRM offers an effective tool for pharmacogenetic screening to guide drug therapy decisions.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...